SCHEMBL13100734

SCHEMBL13100734

ON(O)c1ccc(/C=N/Nc2nc(Nc3ccc(F)cc3)nc(N3CCOCC3)n2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 12/20 0.62
▸ KMT2A Q03164 9/20 0.57
▸ LMNA P02545 8/20 0.57
▸ MEN1 O00255 8/20 0.57
▸ HTT P42858 7/20 0.57
▸ GAA P10253 6/20 0.57
▸ NPSR1 Q6W5P4 4/20 0.57
▸ PKM P14618 1/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ ALDH1A1 P00352 4/20 0.53
▸ TDP1 Q9NUW8 3/20 0.53
▸ CTSL P07711 1/20 0.52
▸ CTSS P25774 1/20 0.52
▸ CTSK P43235 1/20 0.52
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ PIKFYVE Q9Y2I7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13942699 0.83 KMT2A (0.77) MAPTKMT2ALMNAMEN1HTT
SCHEMBL1659816 0.83 MAPT (0.62) MAPTKMT2ALMNAMEN1HTT
SCHEMBL1659812 0.83 MAPT (0.62) MAPTKMT2ALMNAMEN1HTT
SCHEMBL22337232 0.81 KMT2A (0.83) MAPTKMT2ALMNAMEN1HTT
SCHEMBL22737374 0.81 MAPT (0.62) MAPTKMT2ALMNAMEN1HTT
SCHEMBL1660585 0.81 LMNA (0.68) MAPTKMT2ALMNAMEN1HTT
SCHEMBL1660591 0.81 LMNA (0.68) MAPTKMT2ALMNAMEN1HTT
SCHEMBL11899414 0.80 MAPT (0.64) MAPTKMT2ALMNAMEN1HTT
SCHEMBL11899415 0.80 MAPT (0.64) MAPTKMT2ALMNAMEN1HTT
SCHEMBL22737807 0.80 MAPT (0.68) MAPTKMT2ALMNAMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267671-A1 COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS VM DISCOVERY INC. 2010-10-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267671-A1 COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS BAX, BCL2, BAD MAPT 2663/4885KMT2A 4533/4885LMNA 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback